No Detail Found!

Evaluation of Polycythemia Vera Diagnosis and Management: Literature Review

Author(s)
Wafaa Saleh Alghamdi Faculty of Pharmacy, King Khaled University,Abha, KSA,
Meqbel Majed Alshelawi Faculty of Medicine, Medical University of Silesia,Katowice,Poland
Ghufran Mohammed Alshawmali Faculty of Medicine, Medical University of Silesia,Katowice,Poland
Ahmed Saaed Alghamdi Faculty of Medicine, Aljouf University,Sakaka, KSA,
Faisal Abdulaziz Faisal Almulhim Faculty of Medicine, Aljouf University,Sakaka, KSA,
Abrar Hamoud M Albalawi Faculty of Medicine, Tabuk University,Tabuk, KSA,
Hosam Dahaim D Al Harbi Faculty of Medicine, Qassim University,Qassim, KSA,
Faisal Musaad A Alsaleh Faculty of Medicine, Shaqra University,Shaqra, KSA,
Abdullah Omar Bin Shihah Faculty of Medicine, Shaqra University,Shaqra, KSA,
Saja Mohammad Aljehani Faculty of Medicine, King Abdulaziz University,Jeddah, KSA,
Abstract
Background: Polycythemia vera is considered a malignant stem cell disorder and its patients usually experience troublesome symptoms and increased risk of mortality and morbidity. Appropriate diagnosis and management is cardinal in such cases to avoid disease complications and improve the patient's quality of life. Objective: To review the literature that discussed the evaluation and management of cases of polycythemia vera. Method: PubMed database was used for articles selection, and the following keys were used in the mesh ((“polycythemia vera"[Mesh]) AND (“Management” [Mesh]) OR (“Evaluation"[Mesh])). Conclusion: Life-expectancy in polycythemia vera is significantly lower than that of the age- and sex-matched general population. Moreover, despite polycythemia vera is considered as a malignant hematopoietic disorder, many cases do not require chemotherapy because they usually have stable and subtle clinical course. Recent recommendations suggest that all polycythemia vera patients require phlebotomy and once- or twice-daily aspirin if there are no contraindications.
Publication Details
Page(s) 143-145
DOI DOI not available
Published Journal: Archives of Pharmacy Practice, Volume: 11, Issue: 3, Year: 2020

Request the full text from PASTIC

Keywords
Polycythemia Vara, Management Approach, Diagnosis
References
Gerds AT,Dao KH .2017 .Polycythemia vera management and challenges in the community health setting. Oncology, 92(4) : 179-89.
Arber DA,Orazi A,Hasserjian R,Thiele J,Borowitz MJ,Le Beau MM,Bloomfield CD,Cazzola M,Vardiman JW . .The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. -03-643544., 127(20) : 2391-405.
Mehta J,Wang H,Iqbal SU,Mesa R .2013 .Epidemiology of myeloproliferative neoplasms in the United States. Leukemia & lymphoma. 2014 Mar, 813500(3) : 595-600.
Emanuel RM,Dueck AC,Geyer HL,Kiladjian JJ,Slot S,Zweegman S,Te Boekhorst PA,Commandeur S,Schouten HC,Sackmann F,Fuentes AK .2012 .Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. 2012 Nov, 42(33) : 4098.
Tefferi A,Vardiman JW . .Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. , 2404955(1) : 14-22.
JL Spivak . .Polycythemia vera: myths, mechanisms, and management. -12-0349., 100(13) : 4272-90.
Kumar C,Purandare AV,Lee FY,Lorenzi MV .2009 .Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene, 107(24) : 2305-13.
Hensley B,Geyer H,Mesa R .2013 .Polycythemia vera: current pharmacotherapy and future directions. Expert opinion on pharmacotherapy. 2013 Apr, 779671(5) : 609-17.
Scherber R,Dueck A,Johansson PL,Barbui T,Barosi G,Vannucchi AM,Passamonti F,Andreasson B,Ferarri ML,Rambaldi A,Samuelsson J. .2010 .The myeloproliferative neoplasm symptom assessment form (MPN-SAF): an international prospective validation trial in 402 patients. , 21(21) : 4095-95.
Griesshammer M,Gisslinger H,Mesa R . .Current and future treatment options for polycythemia vera. 2015 Jun, 1(6) : 901-10.
Tefferi A,Rumi E,Finazzi G,Gisslinger H,Vannucchi AM,Rodeghiero F,Randi ML,Vaidya R,Cazzola M,Rambaldi A,Gisslinger B .2013 .Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 163(9) : 1874-81.
Tefferi A,Barbui T. . .Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and management. American journal of hematology, 94(1) : 133-43.
Spivak JL . .Polycythemia vera. Current treatment options in oncology. 2018 Feb, 1(2) : 12.
Tefferi A,Guglielmelli P,Larson DR,Finke C,Wassie EA,Pieri L,Gangat N,Fjerza R,Belachew AA,Lasho TL,Ketterling RP . .Longterm survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 Oct, 124(16) : 2507-13.
Hultcrantz M,Kristinsson SY,Andersson TM,Landgren O,Eloranta S,Derolf ÅR,Dickman PW,Björkholm M. .1925 .Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. 2012 Aug, 42(24) : 2995.
Cerquozzi S,Tefferi A .2015 .Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. 2015 Nov;, 95(11) : e366.
Barbui T,Vannucchi AM,Carobbio A,Thiele J,Rumi E,Gisslinger H,Rodeghiero F,Randi ML,Rambaldi A,Pieri L,Pardanani A . .Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis. American journal of hematology, 90(5) : 434-7.
Finazzi G. .2004 .A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). 2004 Jun, 02(5) : 285-8.
Marchioli R,Finazzi G,Landolfi R,Kutti J,Gisslinger H,Patrono C,Marilus R,Villegas A,Tognoni G,Barbui T. .2005 .Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. 2005 Apr, 07(10) : 2224-32.
Bonicelli G,Abdulkarim K,Mounier M,Johansson P,Rossi C,Jooste V,Andreasson B,Maynadié M . .Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients. British journal of haematology, 160(2) : 251-4.
Landolfi R,Di Gennaro L,Barbui T,De Stefano V,Finazzi G,Marfisi R,Tognoni G,Marchioli R . .Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. -08- 042515., 15(6) : 2446-52.
McMullin MF,Harrison CN,Kiladjian JJ . .Treatment target in polycythemia vera. 2013 Apr, 1(16) : 1554-5.
Tefferi A,Vannucchi AM,Barbui T. . .Blood cancer journal. 2018 Jan, 10(1) : 1-7.
0

Citations

0

Downloads

14

Views